Investigating the impact of delivery system design on the efficacy of self-amplifying RNA vaccines by Anderluzzi, Giulia et al.
Article
Investigating the Impact of Delivery System Design
on the Efficacy of Self-Amplifying RNA Vaccines
Giulia Anderluzzi 1,2 , Gustavo Lou 1,2, Simona Gallorini 2, Michela Brazzoli 2,
Russell Johnson 3, Derek T. O’Hagan 3, Barbara C. Baudner 2 and Yvonne Perrie 1,*
1 Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 ORE,
Scotland, UK; giulia.anderluzzi@strath.ac.uk (G.A.); gustavo.lou-ramirez@strath.ac.uk (G.L.)
2 GSK, 53100 Siena 1, Italy; simona.x.gallorini@gsk.com (S.G.); michela.x.brazzoli@gsk.com (M.B.);
barbara.c.baudner@gsk.com (B.C.B.)
3 GSK, Rockville, MD 9911, USA; russell.n.johnson@gsk.com (R.J.); derek.t.o’hagan@gsk.com (D.T.O.)
* Correspondence: yvonne.perrie@strath.ac.uk
Received: 3 April 2020; Accepted: 30 April 2020; Published: 8 May 2020


Abstract: messenger RNA (mRNA)-based vaccines combine the positive attributes of both
live-attenuated and subunit vaccines. In order for these to be applied for clinical use, they require to be
formulated with delivery systems. However, there are limited in vivo studies which compare different
delivery platforms. Therefore, we have compared four different cationic platforms: (1) liposomes,
(2) solid lipid nanoparticles (SLNs), (3) polymeric nanoparticles (NPs) and (4) emulsions, to deliver a
self-amplifying mRNA (SAM) vaccine. All formulations contained either the non-ionizable cationic
lipid 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) or dimethyldioctadecylammonium
bromide (DDA) and they were characterized in terms of physico-chemical attributes, in vitro
transfection efficiency and in vivo vaccine potency. Our results showed that SAM encapsulating
DOTAP polymeric nanoparticles, DOTAP liposomes and DDA liposomes induced the highest
antigen expression in vitro and, from these, DOTAP polymeric nanoparticles were the most potent in
triggering humoral and cellular immunity among candidates in vivo.
Keywords: self-amplifying RNA; liposomes; polymeric nanoparticles; solid lipid nanoparticles;
emulsions; antigen expression; immunogenicity
1. Introduction
Messenger RNA (mRNA)-based vaccines have emerged as a transformative approach, due to their
ability to elicit both humoral and cellular immunity [1–4]. Recently, there has been an increased interest
in applying this technology by numerous companies, including Biomay AG, BioNTech AG, CureVac,
Ethris, eTheRNA BVBA, Moderna Therapeutics, Novartis Vaccines, Ribological GmbH, Tekmira
Pharmaceuticals Corporation and TriLink BioTherapeutics [5]. In contrast to plasmid DNA (pDNA)
vaccines, mRNA does not need to be transported across the nuclear membrane and it can directly induce
antigen expression in the cytosol, such that any potential genomic integration is avoided [6]. Moreover,
mRNA vaccines induce transient antigen expression, while DNA vaccines provide a long-lasting
expression, thus mimicking an acute viral infection. Although a transitory gene expression might
be desirable as it minimizes potential risks of genetic transformation, this inevitably affects mRNA
potency, thus necessitating a dose increase [7]. One strategy to augment mRNA performance is to
include genetic elements that enable self-amplification. Here, the self-amplifying mRNA (SAM) is
based on an alphavirus genome having a positive single stranded RNA (+ssRNA). Importantly, the
structural protein genes of respective alphavirus that enable the formation of infectious viral particles
have been substituted with genes encoding the antigen of interest [8]. However, the virus amplification
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machinery (i.e., polyproteins involved in the replication of the RNA in multiple copies) have been
maintained, hence allowing SAM vaccines to self-amplify over time and consequently inducing more
potent immune responses compared to conventional non-amplifying mRNA vaccines [9–11].
As with other nucleic acid-based technologies, SAM is prone to enzymatic degradation once
injected into the body [12]. Moreover, due to the intrinsic hydrophilic nature and high molecular
weight of SAM, crossing the cell membrane and traversing the endosome for effective delivery
to the cytoplasm presents a formidable challenge. Viral vectors have been used to efficiently
deliver nucleic acid into cell cytoplasm [13,14]; however, because of pre-existing or vaccine-induced
antivector immunity, vaccine potency might be reduced after repeated vaccinations. Physical
methods such as gene gun and electroporation (EP) can also be used to deliver mRNA, although,
these techniques are difficult to scale, and devices are bulky and can be cost-prohibitive for mass
vaccine strategies [15,16]. Considering these obstacles, employing a synthetic delivery vehicle for
the nucleic acid is advantageous. Many studies have reported enhanced immunogenicity when
SAM vaccines are delivered by a particulate delivery system [17–19]. Of the systems tested, lipid
nanoparticles (LNPs) are the most advanced in enabling the clinical potential of genetic drugs,
such as small interfering RNA (siRNA) and mRNA, with several siRNA-LNP systems already
in clinical trials as antiviral, anticancer and genetic disorder therapies [20]. Generally, LNPs
are composed of a complexing amino lipid (either ionizable or non-ionizable), a phospholipid,
cholesterol, a poly (ethylene glycol)-lipid conjugate and the therapeutic nucleic acid [21]. The choice
of complexing lipid is a key element which strongly dictates LNP potency. The ionizable amino
lipids heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino) butanoate (DLin-MC3-DMA) and
2,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane (DLin-KC2-DMA) have low toxicity profiles
and are among the most promising. An siRNA-LNP formulation using DLin-MC3-DMA was recently
approved by the Food and Drug administration (FDA) for the treatment of polyneuropathy of hereditary
transthyretin-mediated amyloidosis in adults [5]. However, the application of LNPs based on DLin- and
other ionizable lipids to deliver nucleic acids may be limited by their high cost. Hence, developing more
commercially competitive carriers with comparable delivery profiles (in terms of SAM protection and
antigen expression) is of great interest. There is a wide range of nanoparticles that may offer advantages
in terms of SAM delivery. Here, we have investigated four non-viral vectors for the delivery of SAM:
(1) liposomes, (2) solid lipid nanoparticles (SLNs), (3) polymeric nanoparticles (NPs) and (4) emulsions.
All particles were formulated containing either the commercially available non-ionizable cationic lipid
1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) or dimethyldioctadecylammonium bromide
(DDA), as they have been extensively investigated as transfection agents or immunostimulants
respectively, for both nucleic acid [22] and subunit vaccines [23]. Furthermore, their safety profile is
well-documented in numerous clinical trials [24–26]. While liposomes, oil-in-water emulsions and
polymeric NPs have been widely reported for the delivery of nucleic acids [27–31], there are limited
publications on the in vivo delivery of DNA or mRNA using SLNs. Moreover, to the best of our
knowledge, a head-to-head comparison of these four different carriers for the delivery of SAM has not
been undertaken.
To formulate these lipid-based nanovectors, we applied scalable manufacturing methods
(microfluidic mixers or microfluidization). Microfluidic mixers are relatively simple and efficient
systems, capable of producing synthetic particles with consistent size and biophysical properties,
including encapsulation of nucleic acids due to reliable laminar flow dynamics [32–34]. To prepare
emulsions, the microfluidization process was used. This method is versatile and has been employed
for the manufacturing of different kinds of formulations [35] for large-scale production. By adjusting
process parameters, a tight control over particle characteristics can be achieved. When considering
the lipid composition to use, LNPs previously evaluated for intramuscular (i.m.) mRNA vaccine
delivery were those originally developed for intravenous (i.v.) delivery of siRNA to the liver [10,36].
However, a recent investigation suggested that the optimal composition of ionizable LNPs is dictated
by the pKa of the ionizable lipid and is route-dependent; specifically, maximum LNP potency after i.v.
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injection was achieved using ionizable lipids with a pKa of 6.2 to 6.4, whilst an optimal pKa range
from 6.6 to 6.8 was suggested for i.m. delivery [37]. However, in a separate study which evaluated
the immunogenicity of a SAM vaccine formulated in LNPs composed of either cationic or ionizable
lipids, it was observed that all LNPs induced equivalent humoral immune responses, indicating that
the use of ionizable lipids is not necessarily a pre-requisite [38]. Therefore, further consideration of
SAM formulation components that offer a lower cost of goods could be advantageous. In addition,
considering the findings of Blakney and co-workers [38], in which LNPs formulated with SAM either
on the interior or exterior of the particles were equally able to protect SAM from enzymatic degradation
and induce comparable humoral immune responses, herein, formulations were prepared with SAM
either encapsulated or adsorbed. To investigate these factors, a SAM encoding rabies virus glycoprotein
G (SAM-RVG) was used and the immunogenicity was compared to that of the licensed rabies vaccine
Rabipur and the GlaxoSmithKline (GSK, Rockville, MD, USA) proprietary cationic nanoemulsion
(CNE56) as benchmarks for the rabies vaccine and mRNA delivery, respectively.
2. Materials and Methods
2.1. Materials
Poly (D, L-lactide-co-glycolide) lactide: glycolide (50:50), mol wt 30,000–60,000, Dimethyl Sulfoxide
(DMSO), Tristearin (Grade II-S, ≥90%), cholesterol, squalene, penicillin-streptomycin, L-glutamine and
Brefeldin A were purchased from Sigma Aldrich Company Ltd., UK. Distearoylphosphatidylcholine
(DSPC), 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (DMG-PEG2000),
Dimethyldioctadecylammonium bromide (DDA) and 1,2-dioleoyl-3-trimethylammonium- propane
(DOTAP) were obtained from Avanti Polar Lipids, US. Ethanol, methanol, 1,1′-Dioctadecyl-3,3,3′,3′-
Tetramethylindocarbocyanine Perchlorate (DilC), Live/Dead Fixable Aqua Dead Cell Stain,
Lipofectamine 2000, Gibco phosphate buffer saline (PBS), Tween 20 and Span 80, RNase A, proteinase
K, Northern Max formaldehyde load dye, Northern Max running 10X buffer, Ambion millennium
RNA, SYBR gold nucleic acid stain marker (10,000X in DMSO), 3 M sodium acetate buffer pH 5.2,
Ribo Green RNA assay kit, opti- Minimal Essential Medium (MEM), Alexa Fluor 488-labeled goat
anti-mouse IgG2a Cross-Adsorbed secondary antibody and allophycocyanin (APC) Zenon antibody
labeling kit for mouse IgG2a and diethylpyrocarbonate (DEPC)-treated water were purchased
from Thermo Fisher, UK. Tris(hydroxymethyl)aminomethane TRIS Ultra-Pure was obtained from
Fisher Scientific, UK. Roswell Park Memorial Institute 1640 medium (RPMI-1640), Hank’s balance
salt solution (HBSS) trypsin ethylenediaminetetraacetic acid (-EDTA,0.25%), Dulbecco’s Modified
Eagle Medium (DMEM) and heat-inactivated fetal calf serum (HI-FCS) were obtained from Gibco,
Italy. 10X Perm/Wash buffer and cytofix-cytoperm solution was obtained from BD Biosciences, UK.
Anti-CD16/CD32 monoclonal antibody (Fc block) was obtained by BD Biosciences, UK. Anti-CD3-APC,
anti-CD28, anti-CD4 BV510, anti-CD107a FITC, anti-IFN-γ Brilliant Violet 785, anti-IL-2 PE-Cy5.5,
anti-TNF Brilliant Violet 605, anti-CD44 V450, anti-IL17 PE and anti-CD8 PE-CF594-conjugated
monoclonal antibodies were obtained from BD Pharmingen, UK. Mini Ready Agarose precast gels 1%
TAE and PLATELIA Rabies II Kit were obtained from Bio-Rad, Italy. Live/dead fixable dead cell stain
near-infraredwas purchased from Life Technologies, Italy. The rabies peptide pool G1/G2/G3 was
obtained from Genescript, US. Rabipur is a trademark owned by the GSK group of companies.
2.2. SAM Synthesis
DNA plasmids encoding the self-amplifying RNAs were constructed using standard molecular
techniques based on previous work by Geall and co-workers [10]. Plasmids were amplified in
Escherichia coli and purified using Qiagen Plasmid Maxi kits (Qiagen, Germantown, MD, USA).
DNA was linearized immediately following the 3′ end of the self-amplifying RNA sequence by
restriction digest. Linearized DNA templates were transcribed into RNA using the MEGAscript T7
kit (Life Technologies, Carlsbad, CA, MA, USA) and purified by LiCl precipitation. RNA was then
Vaccines 2020, 8, 212 4 of 22
capped using the Vaccinia Capping system (New England BioLabs, Ipswich, MA, USA) and purified
by LiCl precipitation before formulation. Self-amplifying RNA encoding the rabies virus glycoprotein
(SAM-RVG) was used in the study.
2.3. Preparation of SAM Formulations
2.3.1. Formulation of Liposome, Solid-lipid Nanoparticles and Polymeric Nanoparticles
Cationic formulations were prepared using the NanoAssemblr Platform (Precision Nanosystems
Inc., Vancouver, BC, Canada) in a staggered herringbone micromixer. Briefly, with respect to liposomes,
lipid mixtures composed of 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) and a cationic
lipid (DOTAP or DDA) were prepared in methanol at 1:1 w/w. Tris buffer pH 7.4 10 mM was used as
aqueous phase. The aqueous: organic flow rate ratio (FRR) and the total flow rate (TFR) were set at 1:1
and 15 mL/min, respectively. Regarding SLNs, a mixture of Tristearin, DOTAP or DDA (1:1 w/w) and 2
mol% of DMG-PEG2000 were dissolved in 1 mL ethanol (70 ◦C) to allow complete lipids dissolution.
Tris buffer pH 7.4 10 mM was used as aqueous phase. Process parameters were fixed at flow rate
ratios of 3:1 (aqueous to solvent) and total flow rates of 15 mL/min. Similarly, to prepare NPs, poly (D,
L-lactide-co-glycolide) lactide: glycolide (50:50), mol/w 30,000–60,000 (PLGA) and DOTAP or DDA 1:1
w/w were dissolved in DMSO and acetate buffer 100 mM, pH 6 was used as aqueous phase. The FRR
and TFR were set up at 1:1 and 15 mL/min. For all formulations, the organic and an aqueous phase
were injected simultaneously in the micromixer, particles were collected in a 15 mL falcon tube and
dialyzed for 1 hour at room temperature against the same formulation buffer for removal of residual
organic solvent (dialysis membrane cut off 14,000 Da).
2.3.2. Formulation of Emulsions
To formulate oil in water (o/w) emulsions, DOTAP or DDA (4.3% w/w) were mixed with squalene
(5.0%, w/w) and heated above cationic lipids transition temperature to allow complete dissolution.
Then, tween (0.5%, w/w), span (0.5%, w/w) and Tris buffer 10mM pH 7.4 were added and the mixture
was vortexed for 1 min to provide a homogeneous feedstock. This primary emulsion was loaded in the
inlet reservoir of an Avestin Emulsiflex C3 (AVESTIN, Inc, Ottawa, Canada) and passed 5 times at
25,000 psi to reduce particle size. CNE56 was prepared by using the method previously described by
Brito and co-workers [39].
2.3.3. Preparation of SAM-Loaded Formulations
To encapsulate SAM-RVG inside formulations, liposomes, SLNs and NPs were formulated with
the addition of RNA 8:1 mol/mol N:P (N in the cationic lipid and P in SAM) in the aqueous phase
prior to micromixing, following the protocol in Section 2.3.1. To load SAM on the surface, the nucleic
acid (8:1 mol/mol N:P) was added dropwise into the suspensions of liposomes, SLNs, NPs and
emulsions under mild stirring. SAM-adsorbing formulations were allowed to complex at 4 ◦C for
at least 2 hours. Prior to in vitro incubation or in vivo administration, formulations were diluted to
dosing concentration.
2.4. Quantification of SAM Loading and Adsorption Efficiency
SAM encapsulation efficiency (EE) was measured using the Quant-iT RiboGreen RNA Assay
Kit following the manufacturer’s instructions. Briefly, 100 µL of the diluted fluorescent dye was
added to each formulation and incubated in absence of light for 5 min. This allowed the dye to
quantitatively bind free nucleic acid. The concentration of non-loaded SAM was determined by
measuring fluorescence (λem = 480 nm, λex = 520nm) using a Synergy H1 Hybrid Multi-Mode Reader
(BioTek Instruments Inc, Winooski, VT, USA). The actual loading was obtained by subtracting the
unloaded SAM to the initial nucleic acid concentration. Furthermore, to quantify SAM adsorption yield,
SAM adsorbing samples were ultracentrifuged for 20 min at 10,000 rpm (Beckman Coulter Airfuge
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Air-Driven Ultracentrifuge, Indianapolis, IN, USA) and the supernatant containing non-adsorbed
nucleic acid was used for SAM quantification. The adsorption efficiency (AE) was calculated using the
method described above.
2.5. Physiochemical Characterization of Formulations
All formulations were characterized in terms of hydrodynamic size (Z-average diameter, the
intensity weighted mean hydrodynamic size), polydispersity index (PDI) and zeta potential (ZP)
by dynamic light scattering (DLS) in a Zetasizer Nano ZS (Malvern Panalytical, Malvern, UK) at
0.1–0.2 mg/mL at 25 ◦C in their respective buffer.
2.6. RNase Protection Assay
To assess the ability of cationic formulations to protect SAM-RVG from RNase degradation, each
SAM-RVG/formulation complex was exposed to 3.8 mAU of RNase A (Ambion, Austin, TX, USA)
per microgram of SAM for 30 min at room temperature. RNase was inactivated by incubation with
proteinase K (Novagen, Merck KGaA, Darmstadt, Germany) at 6.4 mAU/µg of SAM for 10 min at 55 ◦C.
To extract the SAM from lipid formulations, 950 µL of ethanol were added to 50 µL of each sample,
mixed and centrifuged at 12,000 rpm for 25 min. The resulting pellets were resuspended in 25 µL of
DEPC-treated water, mixed with formaldehyde load dye (1:3 v/v), heated at 65 ◦C for 10 min and then
cooled to room temperature on ice. SAM integrity was analyzed by denaturing gel electrophoresis.
0.5 µg of SAM per lane was loaded in a denatured 1% agarose gel in Northern Max 3-(N-morpholino)
propane sulfonic acid (MOPS) running buffer, containing 0.1% of SYBR gold stain (Invitrogen, Carlsbad,
CA, USA), and run at 100 V. Ambion Millennium marker was used as the molecular weight standard.
Gel images were acquired in a Gel Doc EZ imager (Bio-Rad, Hercules, CA, USA).
2.7. Cell Toxicity Assay in Baby Hamster Kidney Cells
Baby hamster kidney cells (BHK) (obtained from American Type Culture Collection, ATCC)
were cultured in complete DMEM (DMEM supplemented with 5% HI-FCS and 1% penicillin and
streptomycin). Cells were grown for 2–3 days at 37 ◦C and 5% CO2. BHK cells were plated at a density
of 5 × 104 cells in 500 µL of DMEM either in the presence (5%) or absence of HI-FCS in each well of
a 24-well plate and incubated for at least 6 hours to allow cell adhesion. Then, cells were incubated
with serial dilutions of SAM-RVG-liposomes, NPs, SLNs and emulsions, starting from a cationic lipid
concentration of 100 µg/mL (which corresponded to a SAM-RVG concentration of 6 µg/mL) through a
3-fold serial dilution. After 16 hours, cells were trypsinized, transferred in 96-well plates and stained
with 100 µL of diluted Live/Dead Fixable Aqua Dead Cell Stain for 20 min at room temperature in the
dark. After two washes with PBS, cells were resuspended in PBS and the percentage of Live/Dead+
cells with respect to untreated control was measured by flow cytometry. All flow cytometry data were
collected on a FACSCANTO II (BD BioScience, San Jose, CA, USA) flow cytometer and analyzed using
FlowJo software 7.6 (BD BioScience, San Jose, CA, USA).
2.8. Cellular Association Efficiency in Baby Hamster Kidney Cells
BHK cells were seeded at a density of 5× 104 cells in 500 µL of DMEM either in the presence (5%) or
absence of HI-FCS in each well of a 24-well plate and incubated for at least 6 hours to allow cell adhesion.
To track cell uptake, SAM-RVG particles were co-formulated with the lipophilic fluorescent dye DilC
(0.2% mol) added in the lipid mixture prior to microfluidics mixing or emulsification. Formulations
were then added at 11 µg/mL of cationic lipid (which corresponded to 0.7 µg/mL of SAM-RVG) and
incubated for 16 hours at 37 ◦C and 5% CO2. As a positive control, BHK were also treated with
Lipofectamine2000 (LF2000) at 5 µL/well following the manufacturer’s instructions. Subsequently,
cells were harvested from the well-plates, washed and resuspended in PBS supplemented with 5%
HI-FCS, and the percentage of DilC+ cells with respect to untreated control was measured by flow
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cytometry in a FACSCANTO II (BD BioScience, San Jose, CA, USA). All data were analyzed in FLowJo
software 7.6 (BD BioScience, San Jose, CA, USA).
2.9. In Vitro Potency of SAM-RVG Formulations
BHK cells (5 × 104 cells/well) were plated as previously described. After 6–8 hours, cells
were incubated for 16 hours with SAM-RVG liposomes, NPs, SLNs and emulsions at SAM-RVG
concentrations of 400, 200 and 100 ng/mL (corresponding to 6, 3 and 1.5 µg/mL of cationic lipid,
respectively). LF2000 was used as a positive control, as mentioned above. Then, cells were
trypsinized and transferred to 96-well plates, washed twice with PBS, fixed and permeabilized
with Cytofix-Cytoperm solution containing 4% paraformaldehyde (PFA). After incubation, cells were
washed twice with PBS and stained with primary antibody dilution (Anti-RVG Ab, clone 24-3F-10)
for 1 hour at room temperature. Then, after washing, cells were incubated with secondary antibody
dilution (Anti Mouse IgG2a) for 1 hour at room temperature in the dark. Finally, cells were washed
and resuspended in PBS for flow cytometry in a FACSCANTO II (BD BioScience, San Jose, CA, USA)
flow cytometer. The percentage of RVG+ formulations was calculated with respect to untreated control
cells. All data were analyzed in FLowJo software 7.6 (BD BioScience, San Jose, CA, USA).
2.10. Evaluation of Immune Responses in Vivo of Different Selected Adjuvants and Their Associated Antigen
2.10.1. Determination of Antigen-Specific Serum Antibody Titers by Enzyme-Linked Immunosorbent
Assay (ELISA)
All animal studies were ethically reviewed and carried out in accordance with European Directive
2010/63/EEC and the GSK policy on the Care, Welfare and Treatment of Animals. Animals were placed
in cages with an individually ventilated caging system and given a standard mouse diet ad-libitum.
Groups of 10 female BALB/c mice (Charles River, Wilmington, MA, USA) aged 6–8 weeks and weighing
about 20–25 g received either 1.5 or 0.15 µg of SAM-RVG encapsulating DOTAP liposomes, DDA
liposomes and DOTAP NPs, or adsorbing CNE56 at days 0 and 28 in 50 µL in the left quadriceps.
Similarly, 50 µL of Rabipur (which corresponded to 1/20 of clinical dose) was administered via i.m.
injection to control groups. Serum samples from individual mice were collected on days 0, 27 and
43 after the first vaccination. Within this study, SAM alone was not tested. Previously published
studies have confirmed that there were no antigen-specific humoral or cellular responses induced by
unformulated SAM [40]. Similarly, Magini et al. immunized mice either with SAM NP or with SAM
M1 (two influenza antigens), and no cross-reactive cellular immune responses were observed [18].
Thus, based on this, SAM alone was not tested to reduce the animal number and be compliant with
3Rs requirements.
RVG-specific IgG titers were determined by ELISA using a commercially available kit (PLATELIA
RABIES II Kit Ad Usum Veterinarium). The assay was performed following the manufacturer’s
instructions. Briefly, each sample was pre-diluted 1:100 in sample buffer and 100 µL was incubated in a
microplate well sensitized with the rabies virus glycoprotein for 60 ± 5 min at 37 ± 1 ◦C. A negative (R3)
and two positive controls (R4a and b) were tested in each run. The positive controls were calibrated
against the World Health Organization (WHO) international standard for rabies immunoglobulin.
R4b (4 equivalent units (EU)/mL) was used to establish a reference curve after successive two-fold
serial dilutions (S5 = 2 EU/mL, S4 = 1 EU/mL, S3 = 0.5 EU/mL, S2 = 0.25 EU/mL, S1 = 0.125 EU/mL).
After three washing cycles with 1× washing solution by the use of a microplate washer (type PW41 or
PW40, Bio-Rad, Hercules, CA, USA), horseradish peroxidase-conjugated protein A (10× concentrated,
to be diluted in 1× washing solution prior to use) was incubated for 1 h ± 5 min at 37 ± 2 ◦C in
a microplate incubator (type IPS, Bio-Rad, Hercules, CA, USA). Following five washes, the linked
peroxidase conjugate was visualized with 3,3’,5,5’-tetramethylbenzidine incubated for 30 ± 5 min
at room temperature. The enzyme reaction was stopped by addition of 1 N sulfuric acid solution.
Absorbance was measured at 450–620 nm with the use of a microplate reader (type PR3100, Bio-Rad
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Hercules, CA, USA) with a specific rabies program. The dose-optical density (OD) response curve
allowed the determination of the titer of each serum. Sera titers were expressed in equivalent unit per
mL (EU/mL).
2.10.2. Intracellular Cytokine Staining (ICS) in Splenocytes
Spleens from three randomly selected immunized mice were removed at day 43 after the first
vaccination. To assess antigen-specific T-cell responses, single splenocyte suspensions were prepared.
In essence, spleens were homogenized in cold HBSS and filtered through 70 µm cell strainers, then
washed with HBSS. Samples were then incubated with RBC lysis buffer (2 mL) at 4 ◦C for 2 min, then
resuspended in complete RPMI (cRPMI) and filtered through cell strainers. Cells were counted in
a Vi-CELL XR cell counter (Beckman Coulter, Brea, CA, USA) and plated at 15 × 106 cells/mL with
anti-CD28 mAb at a final concentration of 2 µg/mL and anti-CD107a FITC (5 µg/mL). As a positive
control, cells were also pre-incubated for 2 hours at 37 ◦C with anti-CD3 mAb (1 µg/mL). Moreover, as
ex vivo restimulation, cells were stimulated for 4 hours with RVG peptide pool G1/G2/G3 (consisting
on 15-mers with 11 amino acid overlaps) at 2.5 µg/mL. Brefeldin A (5 µg/mL) was added to each
condition for the last 4 hours. For flow cytometry analysis, cells were then stained with Live/Dead Near
InfraRed, fixed and permeabilized with Cytofix/Cytoperm, and then incubated with anti-CD16/CD32
Fc block. T-cells were further stained with anti-CD3-APC, anti-CD4 BV510, anti-IFN-γ Brilliant Violet
785, anti-IL-2 PE-Cy5.5, anti-TNF Brilliant Violet 605 and anti-CD8 PE. Samples were acquired on a
LRSII special order (BD Biosciences, San Jose, CA, USA) and analyzed using FlowJo software version
7.6 (BD Biosciences, San Jose, CA, USA). Frequencies of antigen-specific T-cells were calculated after
subtracting the background measured in the corresponding negative control for each cytokine.
2.11. Statistical Analysis
Unless stated otherwise, the results were calculated as mean ± standard deviation (SD). One- way
analysis of variance (ANOVA) followed by Tukey’s post hoc analysis was performed for comparison
and significance was acknowledged for p values < 0.05. Analysis and interpretation were made using
GraphPad Prism 8 (GraphPad Prism software, San Diego, CA, USA) and Microsoft Excel.
3. Results
3.1. Evaluation of Physical Attributes of Liposomes, Solid Lipid Particles, Polymeric Particles and Emulsions
Produced with SAM-RVG
A set of cationic nanoparticles (liposomes, SLNs, NPs and emulsions) either entrapping or
adsorbing SAM encoding the rabies glycoprotein G (RVG) were prepared. Samples were analyzed
according to their physiochemical properties. Criteria applied to screen formulations were based
on previous work on LNP systems [41]. These criteria included: small particle size (with a target
size range of 50–200 nm), monodisperse size distribution (target range, polydispersity index (PDI)
< 0.3) and high loading efficacy (target range of encapsulation/adsorption efficiency (EE/AE)> 90%).
In addition to this, zeta potential was measured to assess the impact of loading SAM into these systems.
The four delivery platforms (liposomes, SLNs, NPs and emulsions) exhibited different
compositions, but all contained the same cationic lipid concentration (either DOTAP or DDA) and
a summary of their physico-chemical characteristics is shown in Table 1 (a scheme showing the
concept/structure of these nanoparticles and encapsulation/adsorption is shown in Supplementary
Figure S1). When considering liposomes formulated without SAM-RVG, both DDA and DOTAP
liposomes were similar in terms of physico-chemical attributes: they were approximately 40–50 nm
in size, with PDI < 0.3 and highly cationic in nature (55–60 mV for DOTAP and 40–50mV for DDA
formulations) (Table 1). When SAM was mixed with these preformed liposomes (referred to as adsorbed
SAM), the particle sizes significantly (p < 0.05) increased (100–145 nm for DOTAP formulations and
170–200 nm DDA formulations) and the zeta potential reduced due to the high (95%–99%) adsorption
Vaccines 2020, 8, 212 8 of 22
of the SAM-RVG (Table 1). When the SAM-RVG was entrapped within the liposomes, the impact
on particle size was less notable for DOTAP liposomes (80–90 nm), which were cationic in nature
(25–30 mV) and with high SAM-RVG loading (Table 1). However, entrapment of SAM-RVG within
DDA liposomes produced particles of similar size to those where the SAM-RVG was adsorbed (Table 1).
Overall, high loading (>95%) was achieved, irrespective of the cationic lipid employed and the
manufacturing method (Table 1).
Table 1. Physico-chemical properties of cationic lipid-based delivery systems. All formulations
were prepared at 1 mg/mL final cationic lipid concentration. Results are represented as
mean ± standard deviation (SD) of three independent batches of each formulation. DOTAP
(1,2-dioleoyl-3-trimethylammonium-propane), DDA (dimethyldioctadecylammonium) NPs (polymeric
nanoparticles), SLNs (solid lipid nanoparticles), size (Z-average diameter), ZP (zeta potential), PDI
(polydispersity index), EE (encapsulation efficiency), AE (adsorption efficiency).
Formulation Type
DOTAP DDA










No SAM 42 ± 4 0.25 ± 0.01 58 ± 3 - 39 ± 6 0.20 ± 0.03 45 ± 7 -
Adsorbed 118 ± 25 0.36 ± 0.20 39 ± 5 97 ± 1 186 ± 15 0.16 ± 0.02 27 ± 4 99 ± 0.1
Entrapped 85 ± 5 0.17 ± 0.02 27 ± 3 96 ± 1 196 ± 9 0.21 ± 0.02 43 ± 3 99 ± 0.2
SLNs
No SAM 64 ± 1 0.11 ± 0.01 30 ± 4 - 70 ± 6 0.26 ± 0.02 46 ± 4 -
Adsorbed 120 ± 2 0.21 ± 0.02 15 ± 2 97 ± 1 201 ± 62 0.29 ± 0.04 26 ± 4 99 ± 0.1
Entrapped 187 ± 17 0.14 ± 0.01 23 ± 1 98 ± 1 - - - -
NPs
No SAM 39 ± 9 0.13 ± 0.07 49 ± 6 - 58 ± 3 0.07 ± 0.02 38 ± 5 -
Adsorbed - - - - 267 ± 34 0.27 ± 0.05 26 ± 4 99 ± 0.1
Entrapped 198 ± 6 0.23 ± 0.02 26 ± 6 98 ± 1 - - - -
Emulsions
No SAM 150 ± 7 0.05 ± 0.01 38 ± 2 - 196 ± 24 0.19 ± 0.07 38 ± 3 -
Adsorbed 182 ± 33 0.19 ± 0.01 35 ± 2 95 ± 2 209 ± 9 0.08 ± 0.03 35 ± 3 90 ± 0.5
Entrapped - - - - - - - -
In the case of the SLNs, when formulated in the absence of SAM-RVG, the particles were 65–75 nm,
with a low PDI (<0.3), and cationic in nature, irrespective of the cationic lipid used (Table 1). When
these cationic SLNs were mixed with SAM-RVG, a significant (p < 0.05) increase in particle size was
again seen in combination with a reduction in zeta potential and high SAM-RVG loading (>95%;
Table 1). As for the liposomes, the DDA-based SLNs were larger than their DOTAP counterparts
(120 nm for DOTAP compared to 200 nm for DDA-based SLNs; Table 1). When SLNs were formulated
to entrap SAM-RVG, only SLNs containing DOTAP could be prepared as notable aggregation was
observed during DDA-based SLNs entrapping SAM-RVG manufacturing. Polymeric nanoparticles
formulated with either DOTAP or DDA were 40–60 nm in size, with a low PDI and a high zeta potential
(Table 1). When these nanoparticles were mixed with SAM-RVG, the DOTAP-based nanoparticles
precipitated and the DDA-based nanoparticles significantly (p < 0.05) increased in diameter, up to
260–270 nm (Table 1). In contrast, when the polymeric nanoparticles were formulated to entrap
SAM-RVG, only those containing DOTAP could be prepared with vesicle sizes of approximately 200 nm
(PDI 0.23), cationic zeta potential (20–30 mV) and high (>95%) SAM-RVG incorporation. Finally, prior
to addition of SAM-RVG to emulsions, globule sizes were 140–160 nm for DOTAP-based emulsions
and 170–210 nm for DDA-based emulsions (Table 1). Both were cationic in nature (30–40 mV) and with
the addition of SAM-RVG, high adsorption was noted (>95%) combined with an increase in globule
size and a drop in zeta potential (Table 1). Given the construct of emulsions, SAM-RVG entrapment
could not be considered.
Overall, prior to the addition of SAM-RVG, the choice of cationic lipid used (DOTAP versus DDA)
did not notably impact on particle size and all systems were highly cationic (Table 1). On the addition
of SAM-RVG (either entrapped or adsorbed), all formulations had high loading and particle sizes
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increased, and generally, DDA-based formulations were larger in size (Table 1). When liposomes, SLNs,
NPs and emulsions were tested for their ability to protect their associated SAM-RVG, formulations
showed variable protection with no clear trend in terms of either delivery system or DOTAP versus
DDA (Supplementary Figure S2).
3.2. Cell Association of SAM-RVG-Loaded Liposomes, SLNs, NPs and Emulsions in BHK Cell Line
Based on these initial studies, the various formulations outlined in Table 1 progressed into in vitro
studies. Initially, the cytotoxicity of all formulations in BHK cells was quantified after 16 hours
by the amine reactive dye Live/Dead to identify the sub-toxic concentration to work at. Generally,
DOTAP formulations were less toxic compared to DDA formulations, with cells remaining viable
at concentrations up to 33 µg/mL for DOTAP-based delivery systems compared to 11 µg/mL for
DDA-based delivery systems (Figure 1A,B). The exception to this was the emulsions formulations,
with cells having high viability when treated with up to 100 µg/mL for both the DOTAP and DDA
formulations (Figure 1). Based on these results, delivery system concentrations of 11 µg/mL or less were
used within the cell studies. To investigate the impact of cationic lipid choice on cellular association,
fluorescently labelled DOTAP- (Figure 1C) and DDA (Figure 1D)-based formulations were prepared.
Initially, all delivery systems were incubated for 16 hours in cells in FCS-free medium or complete
medium (i.e., FCS-free or medium containing 5% FCS, respectively; Figure 1C,D). By expressing
particle cellular association as percentage of DilC+ cells, there was no significant difference between
the various DOTAP- and DDA-based delivery systems (Figure 1C,D); thus, despite differences in
physico-chemical properties, the different cationic lipid used and the different cells’ growing conditions
(+/− 5% FCS), formulations were associated with fibroblasts to the same extent, with an average
percentage of DilC-positive cells of around 95% (Figure 1C,D).
Vaccines 2020, 8, x 9 of 22 
 
Overall, prior to the addition of SAM-RVG, the choice of cationic lipid used (DOTAP versus 
DDA) did not notably impact on particle size and all systems were highly cationic (Table 1). On the 
addition of SAM-RVG (either entrapped or adsorbed), all formulations had high loading and particle 
sizes increased, and generally, DDA-based formulations were larger in size (Table 1). When 
liposomes, SLNs, NPs and emulsions were tested for their ability to protect their associated SAM-
RVG, formulations showed variable protection with no clear trend in terms of either delivery system 
or DOTAP versus DDA (Supplementary Figure S2). 
3.2. Cell Association of SAM-RVG-Loaded Liposomes, SLNs, NPs and Emulsions in BHK Cell Line 
Based on these initial studies, the various formulations outlined in Table 1 progressed into in 
vitro studies. Initially, the cytotoxicity of all formulations in BHK cells was quantified after 16 hours 
by the amine reactive dye Live/Dead to identify the sub-toxic concentration to work at. Generally, 
DOTAP formulations were less toxic compared to DDA for ulations, ith cells re aining viable at 
concentrations up to 33 µg/mL for DOTAP-based delivery systems compared to 11 µg/mL for DDA-
based delivery systems (Figure 1A,B). The exception to this was the emulsions formulations, with 
cells having high viability when treated with up to 100 g/ L for both the DOTAP and DA 
formulations (Figure 1). Based on these results, delivery system concentrations of 11 µg/mL or less 
were used within the cell studies. To investigate the impact of cationic lipid choice on cellular 
association, fluorescently labelled DOTAP- (Figure 1C) and DDA (Figure 1D)-based formulations 
were prepared. Initially, all delivery systems were incubated for 16 hours in cells in FCS-free edium 
or co plete medium (i.e., FCS-free or medium containing 5% FCS, respectively; Figure 1C,D). By 
expressing particle cellular association as percentage of DilC+ cells, there was no significant difference 
between the various DOT P- and DDA-based delivery systems (Figure 1C,D); thus, despite 
differences in physico-chemical properties, the different cationic lipid used and the different cells’ 
growing conditions (+/− 5% FCS), formulations were associated with fibroblasts to the same extent, 
with an average percentage of DilC-positive cells of around 95% (Figure 1C,D). 
 
Figure 1. Cell viability and cell association of delivery platforms with baby hamster kidney (BHK) 
cells. Cytotoxicity (A and B) and cell association (C and D) in BHK cell of DOTAP-based (A and C) 
and DDA-based (B and D) liposomes, SLNs, NPs and emulsions. Lipofectamine 2000 (LF2000) was 
used as positive control. For cell viability, cationic lipid concentrations of 3.7 to 100 µg/mL (N:P ratio 
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Figure 1. Cell viability and cell association of delivery platforms with baby hamster kidney (BHK)
cells. Cytotoxicity (A,B) and cell association (C,D) in BHK cell of DOTAP-based (A,C) and DDA-based
(B,D) liposomes, SLNs, NPs and emulsions. Lipofectamine 2000 (LF2000) was used as positive control.
For cell viability, cationic lipid concentrations of 3.7 to 100 µg/mL (N:P ratio of 8:1) were tested. For cell
association, the results represent percentage of 1,1’-dioctadecyl-3,3,3’,3’-tetramethylindocarbocyanine
perchlorate (DilC)-positive BHK cells after 16 hours of incubation with 11 µg/mL of DOTAP-based
(C) and DDA (D) formulations in either 5% fetal calf serum (FCS) or FCS-free media. Results are
represented as mean ± SD of 3 independent experiments.
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However, differences in association efficiency between the formulations were evident when
analyzing mean fluorescence intensity values (MFI) (Figure 2). The mean fluorescence intensity
measured by flow cytometry is equivalent to the amount of fluorescent dye associated with BHK,
which is directly proportional to the product of the number of particles by particles’ fluorescence
intensity. Figure 2A shows that the MFI of DOTAP SLNs and NPs was significantly higher (p < 0.05)
compared to the liposome- and emulsion-based formulations: SLNs and NPs MFI was >24,300, whilst
the DOTAP-based liposome and emulsion systems had MFI < 14,300 (Figure 2A). With the DDA-based
delivery systems, only the NPs showed significantly (p < 0.05) higher levels compared to the other
formulations (Figure 2B) and in general, moving from DOTAP to DDA reduced the overall cell uptake
based on MFI (Figure 2A,B). When these studies were conducted in FCS-free conditions (Figure 2C,D),
whilst absolute values were lower compared to those measured in complete medium, a similar trend
was noted across the delivery systems and comparing the two different cationic lipids (Figure 2).
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Figure 2. Cell association of formulations in BHK cell line expressed as mean fluorescence intensity
(MFI). Mean fluorescence intensity of BHK cells after 16 h incubation with DOTAP-based (A,C) and
DDA-based (B,D) liposomes, SLNs, NPs and emulsions in either 5% FCS (A,B) or FCS-free media
(C,D). Results are represented as mean ± SD of 3 independent experiments.
3.3. In Vitro Potency Assay with SAM-RVG Formulations
Figure 3 represents the percentage of RVG-positive cells after 16 h incubation of SAM-RVG-loaded
DOTAP (Figure 3A,C) or DDA (Figure 3B,D) particles at different antigen concentrations in complete
medium. Overall, the transfection efficiency was SAM dose-independent: within the concentration
range tested, increasing SAM-RVG content did not result in enhanced antigen expression. However,
although all delivery systems tested did transfect fibroblasts, the potency of the transfection varied.
In complete medium, with the DOTAP-based delivery systems, at SAM-RVG of 100 ng/mL, NPs and
liposomes (with SAM-RVG entrapped or adsorbed) transfected between 40% and 60% of BHK cells,
whilst for the rest of the delivery systems, the percentage of RVG+ cells was <30% (Figure 3A). Absolute
values of RVG+ cells were not significantly different between the liposomes, SLNs and NPs at lower
concentrations (Figure 3A); however, at SAM-RVG concentrations of 400 ng/mL, NPs and liposomes
showed transfection efficiencies comparable to Lipofectamine 2000 (LF2000), whilst the percentage of
RVG+ cells after treatment with SLNs and emulsion were lower (<50% %RVG+) compared to LF2000
(Figure 3A). A similar pattern was observed with DDA-based formulations (Figure 3B). Due to a
possible inhibitory effect by serum proteins on gene delivery, in vitro potency (IVP) testing was also
performed in the absence of serum in culture (Figure 3C,D). Particles-mediated antigen expression in
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serum-free medium followed a similar trend to that observed in complete medium conditions, but
overall, the percentage of transfected cells increased in FCS-free conditions (Figure 3C,D).
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3.4. Immunogenicity of Different Vaccine Candidates Encoding RVG after Intramuscular Injection
Immunogenicity of SAM-RVG vaccines was performed in BALB/c mice. Candidates were selected
based on a down-selection strategy with those showing appropriate physical attributes progressing
in vitro, and then based on in vitro potency (IVP), three delivery systems progressed to the in vivo
study: DOTAP liposomes, DDA liposomes and DOTAP NPs, as summarized in Table 2. These three
candidates were compared to Rabipur, a commercial inactivated rabies virus vaccine, and to CNE56.
The SAM-RVG dose range tested was based on previous findings on LNP systems used for SAM
delivery in mice [10]. Two different antigen doses were used to evaluate any correlation between SAM
dosing and immune response.
Figure 4 shows the immunogenicity of SAM-RVG vaccines induced by the selected delivery
systems at different time oints. A study conducted in collaboration with WHO reported a concor ance
of 95% between IgG titers from this ELISA method a d the rapid fluorescent focus inhibition test
(RFFIT) test, a reference method for detection of protective levels of rabies neutralizing antibodies in
sera [42,43]. Therefore, IgG titers measured within the current study can be correlated with functional
neutralizing antibodies. Figure 4A shows the results four weeks after the first injection. It can be seen
that, whilst mice which received CNE56 with adsorbed SAM showed dose-dependent responses, with
all three of the other formulations, the lower dose (0.15 µg/dose) gave equivalent or even improved
responses in terms of both the number of responders and the geometric mean titers (GMT) compared
to the higher dose (1.5 µg/dose, Figure 4A). With mice that received NPs, the low dose of SAM
(0.15 µg/dose) promoted antibody titers, not significantly different to those induced by Rabipur and
CNE56 with a SAM dose of 0.15 µg. Moreover, at both SAM concentrations, NPs GMT was above 0.5
EU/mL, which is considered a positive protective antibody response to rabies vaccination according to
WHO [44]. DOTAP NPs were also more effective than both liposome formulations (Figure 4A). When
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comparing between the liposome formulations, there was no significant difference in terms of cationic
lipid used within the formulation (DOTAP versus DDA; Figure 4A).
Table 2. Schematic representation of criteria applied to DOTAP- or DDA-based liposomes, solid lipid
nanoparticles and emulsions to down-select formulations to progress to in vivo studies.
Progression Selection Criteria
Cationic Lipid Delivery Platform Method ofAssociation
Progress to In Vitro Based
on Physio-Chemical
Attributes
Progress to In Vitro
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At day 43 (two weeks after the second immunization), all formulations increased in titers
(Figure 4B) and generally, the pattern in terms of responses matched those seen four weeks after
the first injection (Figure 4A). Of the three novel formulations, again, NPs generally elicited higher
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and more consistent glycoprotein G-specific IgG levels than both liposome formulations (Figure 4B).
Comparing between the liposomes, whilst both formulations elicited comparable antibody titers at a
0.15 µg/dose of SAM, at the higher dose, DOTAP liposomes were more potent than DDA liposomes
(Figure 4B) and boosted glycoprotein G-specific titers approximately 3-fold (GMT 2.25) relative to
DDA liposomes (GMT 0.67) (Figure 4B). From these results, out of the novel formulations tested, NPs
gave the most robust responses and were as potent as CNE56 at SAM concentrations of 0.15 µg/mL
both prior to and post booster injection; however, CNE56 at SAM concentrations of 1.5 µg/mL gave
significantly high responses (Figure 4). There was also no significant difference between NPs and the
commercial vaccine Rabipur after the first injection, but after the second immunization, Rabipur was
significantly (p < 0.05) more potent than the NP and liposome formulations (Figure 4).
After two immunizations, all animals had measurable RVG-specific CD4+ and CD8+ T-cell
responses (Figure 5). Although not statistically significant, NPs at 1.5 µg of SAM induced the highest
frequency of RVG-specific CD4+ T-cells, compared to all the other formulations, including Rabipur
and CNE56 (0.46% compared to 0.35% and 0.33%, respectively; Figure 5A). At 0.15 µg of SAM,
the RVG-specific CD4+ T-cells induced by SAM encapsulating NPs decreased to 0.25%. A similar
dose-response was observed for the DOTAP liposome formulation, though the RVG-specific CD4+
T-cells’ frequencies were lower (0.21 and 0.1 at 1.5 and 0.15 µg, respectively). However, this was not
evident for the DDA formulation (between 0.8% and 1.5% regardless of the SAM dose; Figure 5A).
With respect to the cell phenotype, the quality of the CD4+ T cell response was similar for all the tested
formulations: overall, CD4+ T-cells were poly-functional, expressing IFN-γ in combination with TNF
and/or IL-2, a typical feature of mature effector CD4+ T-cells (Figure 5A). As expected, a combination of
Th0 (IL-2+/TNF-α+, TNF-α+ and IL-2+) and Th1 (IFN-γ+/IL-2+/TNF-α+ and combinations) phenotype
was observed in CD4+ T-cells two weeks after the second immunization (Figure 5A). Regarding
CD8+ T-cell responses, again, NPs induced the highest frequency of RVG-specific CD8+ T-cells in a
dose-dependent manner (2.6% and 0.55% at 1.5 and 0.15µg, respectively; Figure 5B). NPs appeared to be
more potent than CNE56 and as potent as Rabipur, whilst the DOTAP and DDA liposome formulations
were not efficient in inducing CD8+ T-cells (Figure 5B). Comparing NPs and Rabipur-vaccinated mice,
the quality of the response was slightly different, with more poly-functional CD8+ T-cells in the group
of Rabipur-vaccinated mice, representing mature effector antigen-specific CD8+ T-cells (Figure 5B).
However, it might be worth noting that the aforementioned observations were qualitative and due to
the low number of animals analyzed, it was not possible to draw any statistical conclusions. Generally,
NPs at SAM concentrations of 1.5 µg/mL were significantly more potent than both liposomes in
inducing both cytokines producing CD4+ and CD8+ T-cells (p < 0.05) and as potent as both CNE56
and Rabipur.
The effector phenotype of CD4+ and CD8+ T-cells was further evaluated by quantifying the
surface expression of CD107a, a marker of degranulation which whose expression correlates with
the in vivo cytotoxicity of T-cells [45] (Figure 6). After two immunizations with SAM-RVG at two
different doses in combination with NPs or liposomes, the majority of RVG-specific CD4+ T-cells were
CD107a- (Figure 6A). Similar results were obtained for CNE56 and the commercial vaccine Rabipur.
This suggested that SAM formulations did not induce cytotoxic CD4+ T-cells (Figure 6A). However,
considering specific CD8+ T-cells, candidates were less potent than Rabipur in inducing cytotoxic
T-cells, in line with the phenotype observed (less polyfunctional CD8+ T-cells; Figure 6B).
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T-cells 2 weeks after two intramuscular immunizations spaced 4 weeks apart in BALB/c mice. Mice were
immunized with either 1.5 or 0.15 µg/dose of self-amplifying RNA expressing rabies G glycoprotein
adjuvanted with either polymeric nanoparticles (NPs), DOTAP liposomes or DDA liposomes, and
spleens from 3 mice randomly selected out of the group were tested. Candidates were co pared with
the commercial vaccine Rabipur (1/20 of hu an dose) and GSK trademark CNE56 as positive controls.
Splenocytes were stimulated with rabies G1/G2/G3 peptide, stained for intra-cellular cytokines, and
analyzed by flow cytometry. The color code indicates t e different combinations of cytokine produced
by the respective cells. Unstimulated cells were used as control. Refer to Figure S3 in the Supplemental
Material for the gating strategy.
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Figure 6. Percentages of cytotoxic CD4+ or CD8+ T-cells. The induction of rabies-specific CD4+ or CD8+
T-cells by either 1.5 or 0.15 µg/dose of SAM encapsulating nanoparticles (NPs), DOTAP liposomes and
DDA liposomes was characterized 2 weeks after the second immunization. Spleens from 3 mice were
randomly selected from each group. Candidates were compared with the commercial vaccine Rabipur
(1/20 of human dose) and GSK trademark CNE56 as positive controls. Surface expression of CD107a on
splenocytes stimulated in vitro with rabies G1/G2/G3 peptide was assessed by flow cytometry. Data
show the frequency of cytokine-secreting (A) CD4+ or (B) CD8+ T-cells that express (blue bars) or do
not express (orange bars) CD107a. Unstimulated cells were used as control. Refer to Figure S3 in the
Supplemental Material for the gati g strategy.
4. Discussion
SAM vaccines offer strong potential compared with conventional vaccines as they can be produced
by a simple, synthetic and cell-free process. Furthermore, SAM vaccines can encode not only the antigen
but also the viral replication machinery that enables intracellular mRNA amplification and protein
expression [46]. Co-formulation of SAM and lipid nanoparticles (LNPs) further supports increased
vaccine potency, as LNPs augment in vivo stability by preserving the nucleic acid from enzymatic
degradation and facilitating accumulation within cell cytosol [10]. However, other formulation
platforms may also offer similar advantages in terms of SAM delivery. Cationic liposomes were
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the first to be used extensively for the delivery of nucleic acid therapeutics, such as pDNA [23,47]
and siRNA [48,49]. Since the early works conducted in the 1980s [50,51], the number of studies
aiming to evaluate the potential of liposomes for gene therapy have markedly increased. To date,
cationic liposomes have been applied in more than 100 clinical trials, mainly for cancer therapy and
monogenic diseases like cystic fibrosis [52]. Nanoemulsions have also been described as a means to
improve transfection of nucleic acids and they have been evaluated in humans for a range of vaccine
candidates, including those targeting herpes simplex virus (HSV), human immunodeficiency virus
(HIV), hepatitis C virus (HCV) and cytomegalovirus (CMV) [53–55]. More recently, a cationic version
of the squalene-based emulsion-MF59, which contains the cationic lipid DOTAP- has been used to
potentiate the immune response of a SAM in both rabbits and non-human primates (NHP) [39], and
recently entered a phase I clinical trial. Furthermore, the combination of DNA/mRNA with polymeric
nanoparticles was successfully employed in gene therapy [56]. Polyethyleneimine (PEI) is one of
the most prominently used cationic polymers to formulate nanoparticles for nucleic acid delivery.
For example, it was observed that transfection of the HPV16 E7 gene with PEI-based nanoparticles
was efficient in COS-7 cells, but toxicity was observed in vivo [57]. Therefore, more biodegradable
polymers such as poly(lactic-co-glycolic acid)(PLGA) or polylactic acid (PLA) are preferred, as they
are more biocompatible, and their degradation rate can be tuned to control the release of nucleic acid
into the cytosol. Currently, most of the NPs-based RNA delivery systems are approved for clinical
evaluation in cancer therapy, virus infection, cystic fibrosis and hypercholesterolemia [29]. In contrast
to the aforementioned delivery systems, SLNs are less widely explored [34,58]; although promising,
their main application remains as solubilizing agents for the delivery of poorly soluble drugs [59] or in
the cosmetic and food industry [60], and only limited studies report their use as vaccine adjuvants,
especially in combination with nucleic acids [61,62].
Within this study, we have investigated a set of cationic formulations for SAM vaccine delivery:
liposomes, NPs, SLNs and emulsions. These alternative non-viral carriers were considered as a
potentially more cost-effective strategy for in vivo delivery of SAM. To manufacture these systems,
we adopted either microfluidics or microfluidization, which supported production of narrow-size
and homogeneous empty or SAM-encapsulating/adsorbing particles. All formulations included a
cationic lipid (either DOTAP or DDA), to produce cationic nanoparticles. Changing from DOTAP to
DDA produced larger particles whilst still maintaining comparable surface charge values. This size
modification of DDA-based carriers may be due to the intrinsic rigidity of particles formulated with
this cationic lipid [63,64]. The strategy of using positively charged lipids for nucleic acid delivery
is widely accepted, as they enhance antigen loading owing to charge-to-charge interactions with
nucleic acid [65] and promote binding with the negatively charged cell membrane, thus facilitating cell
uptake [66,67]. Furthermore, the combination of cationic and anionic lipids favors the formation of
non-bilayer structures that enhance endosomal escape and cargo release within the cytosol [68]. Several
publications suggest that a cationic charge is a crucial factor for retention of the vaccine at the injection
site, thus prolonging antigen presentation to the innate immune cells [69]. The increased permanency
of SAM-loaded particles at the injection site might be of interest as it was reported that internalization of
mRNA vaccines occurs primarily by nonimmune cells at the injection site and the antigen is expressed
mainly by muscle cells, fibroblast and keratinocytes [70]. However, some publications hypothesized
that a strong depot effect might not be required for these types of formulations, thus the role of SAM
deposition at the injection site remains unclear [37]. Despite differences in physico-chemical attributes,
all formulations were able to protect SAM-RVG from ribonuclease degradation. As previously reported,
protection from enzymatic degradation significantly increased levels of reporter gene expression
compared to naked RNA and lowered variability of expression between animals [10,53].
Cationic particles readily associated with BHK cells in vitro, with approximately 95% Dilc+
cells regardless of the presence or absence of serum proteins. Although the uptake mechanism of
SAM-loaded particles was not investigated in the present study, we speculate that the association
pathway of non-ionizable cationic particles did not involve the endogenous ligand Apolipoprotein
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E (ApoE). Accordingly, literature reported that ApoE plays a major role as an endogenous targeting
ligand for ionizable LNPs, but not cationic LNPs [71]. The interaction of ionizable LNPs siRNA
with ApoE was crucial for efficient hepatocyte gene silencing after i.v. administration [71], whereas
this mechanism might not be essential for the delivery of SAM administered i.m. [71]. In vitro
potency (IVP) experiments showed that DOTAP polymeric nanoparticles and both DDA and DOTAP
liposomes induced the most consistent antigen expression in BHK cells. The improved ability of
either DOTAP or DDA liposomes to elicit antigen expression might be helped by the presence of the
fusogenic phospholipid DOPE in the liposome formulations. The cone-like shape lipid geometry
can stabilize the non-bilayer hexagonal (HII) phase, which is found in transitional structures during
membrane fusion and/or bilayer disruption [72,73]. On the other hand, the potency of polymeric NPs
to transfect fibroblasts might also be attributed to the presence of the biodegradable polymer PLGA
in the formulation [74]. The mechanism of the enhanced therapeutic effect given by PLGA has been
elucidated by Panyam and co-workers [75]. They postulated that at the acidic pH of endo-lysosomes
(pH between 4 and 5) [76], the lactic and glycolic acid monomers of PLGA become protonated,
hence interacting with the negatively charged membrane, leading to their escape into cytoplasmic
compartment. The mechanism of escape proposed within the cited paper was attributed to localized
destabilization of the endo-lysosomal membrane at the point of contact with PLGA NP, followed by
extrusion of the NP through the membrane [75].
Our immunogenicity studies in mice showed that, after a single immunization, NPs induced
IgG titers comparable to the commercial vaccine Rabipur and CNE56. The strong correlation
between the aforementioned IgG titers and the RFFIT test established by WHO [42,43] suggested that
immunoglobulin titers measured within this paper could be correlated with functional neutralizing
antibodies. NPs GMT was above the level of protective antibody response to rabies vaccination
reported by WHO [44]. After the boost, NPs at 0.15 µg/dose of SAM were as potent as CNE56 to elicit
antibody titers in vivo. PLGA nanoparticles for nucleic acid delivery have attracted strong interest as an
alternative to the commonly used polycationic carriers that can be toxic and/or non-biodegradable [74].
PLGA has been licensed by the FDA and European Medicines Agency (EMA) for the delivery of
therapeutics via subcutaneous, intradermal, intramuscular and mucosal routes [77,78]. PLGA has also
been adopted in the manufacturing of biomedical devices like surgical sutures and bone implants [79].
To date, 15 PLGA-based products are marketed for clinical use as cancer vaccines [80]. In order to
increase nucleic acid association, PLGA nano/microparticles are usually formulated with cationic
materials such as DOTAP or cetyltrimethylammonium bromide (CTAB) [81]. Accordingly, PLGA/CTAB
microparticles entered stage I clinical trials by Novartis for HIV-1 DNA vaccination [82]. In addition,
PLGA-encapsulated DNA encoding human papillomavirus (HPV) antigen has been tested in phase II
human clinical trials [83].
Despite promising results on antigen transfection in vitro, DOTAP and DDA liposomes were less
potent than NPs to elicit a robust humoral response in mice and the variability among mice was high.
The poor correlation between in vitro protein expression and in vivo immunogenicity was also reported
by Blakney and co-workers, where different LNPs (based either on DDA, DOTAP or C12-200) showed
different in vitro and in vivo antigen expression, but comparable antibody titers levels in vivo [38]. This
was also seen elsewhere [37,84]. Interestingly, after the boost, DOTAP liposomes were more efficient in
eliciting IgG titers compared to DDA counterparts. This fact could be explained by considering studies
of Hassett and co-workers, who demonstrated a relationship between both immunogenicity and
expression in vivo and particles size, with the best performing formulations being 75–95 nm [37]. As
discussed previously, DOTAP liposomes were around 75 nm in size, while DDA particles diameter was
around 200 nm. This finding might correlate with observed differences in IgG titers between DOTAP
and DDA liposomes. DDA is commonly employed as a potent adjuvant which has previously been
shown to enhance immunogenicity of experimental subunit vaccines [85–87]. It is widely accepted
that DDA exerts a strong stimulatory effect by activating innate immunity, cell-mediated immunity
and delayed-type hypersensitivity [88,89]. However, strong activation of the innate immune response
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may also offer drawbacks, as it could hamper the amplification of the RNA replicon and the expression
of the encoded antigen, due to overexpression of type 1 IFN [90]. This would inevitably affect SAM
efficacy in vivo. Moreover, it was observed that fully saturated lipids might not be suitable for mRNA
and siRNA delivery, while lipids containing 2 to 3 unsaturated hydrocarbons assume a non-bilayer HII
structure more rapidly. These structures are known to destabilize endosomal membrane and facilitate
RNA release in the cytosol [91].
The T-cell assay performed in splenocytes from mice that received the boost showed that
frequencies of cytokine-producing CD4+ and CD8+ T cells induced by SAM-encapsulating NPs
were comparable to those of Rabipur and CNE56. Moreover, NPs-induced CD4+ T-cells showed a
Th1 phenotype, with several polyfunctional cells. SAM-NPs induced a similar phenotype in CD8+
T-cells to Rabipur, however, the quality of released cytokines was different. This finding correlated
with the observed cytotoxic profile and was in line with what has been already documented in the
literature [19,39,54,92]. Overall, results reported here showed differences in quantity rather than
quality of cytokines proliferation induced by the SAM-loaded candidates tested, with NPs eliciting
higher CD4+ and CD8+ cytokines release compared to both liposomes. This was consistent with
differences in immunogenicity observed within this work. It has been seen that PLGA might play a
role in directing the immune response. For instance, the loading of Hepatitis B core antigen into PLGA
NPs induced a stronger cellular immune response as compared with Hepatitis B core antigen alone in
a mouse model [93]. Moreover, a correlation between particle size and immunogenicity was evaluated
previously, with NPs ranging from 200 to 600 nm associated with higher levels of IFN-γ production
related to a Th1 response, whereas increasing particles size up to 2000 nm promoted IL-4 secretion
related to a Th2 response [94].
5. Conclusions
The present study demonstrates that it is possible to effectively formulate and manufacture
four different cationic formulations produced by two manufacturing methods: microfluidic mixer
and microfluidization. Our data showed that the choice of delivery platform and method of SAM
association (entrapment versus adsorption) impacts on the physico-chemical attributes. Prior to
the addition of SAM, liposomes and nanoparticles were <65 nm, whilst emulsions were 150 nm.
The addition of SAM increased particle size and lowered their zeta potential, especially when adsorbed
to the DDA-based particles. Based on in vitro potency, liposomes (DOTAP or DDA) entrapping
SAM and DOTAP nanoparticles entrapping SAM progressed to in vivo testing. However, the lack of
correlation between in vitro antigen expression and in vivo immune response is noted, thus indicating
that in vitro expression alone is insufficient to identify improved SAM vaccine formulations. In vivo,
DOTAP NPs are effective in inducing robust immune responses in mice, with comparable potency to
the commercial vaccine Rabipur and the benchmark CNE56. Generally, the DOTAP NPs formulation
identified herein is a promising alternative synthetic delivery carrier to commonly used LNPs and has
the potential to be further optimized for the delivery of a self-amplifying RNA vaccine platform.
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